Cytrx Corp (CYTR) 2.96 $CYTR
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics
PR Newswire - Wed Feb 04, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Celgene Corporation (NASDAQ: CELG), CytRx Corporation (NASDAQ: CYTR), Amicus Therapeutics Inc. (NASDAQ: FOLD), and United Therapeutics Corporation (NASDAQ: UTHR). Free research report on ARIAD Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=ARIAD%20P...amp;s=ARIA. On Tuesday, February 03, 2015, the NASDAQ Composite ended at 4,727.74, up 1.09%, the Dow Jones Industrial Average advanced 1.76%, to finish the day at 17,666.40, and the S&P 500 closed at 2,050.03, up 1.44%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 811.48, up 0.65%, with the index also advancing 4.16% in the previous three months. Register for your complimentary reports at the links given below.
UTHR: 151.11 (+3.59), CYTR: 2.96 (+0.23), ARIA: 7.35 (+0.45), FOLD: 8.36 (-0.11), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
CytRx to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015 in New York City
PR Newswire - Mon Feb 02, 8:00AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 5:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
CYTR: 2.96 (+0.23)
CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 3:45PM CST
CytRx Corporation (CYTR) announced encouraging data on its oncology candidate, aldoxorubicin.
JNJ: 99.62 (+1.18), CYTR: 2.96 (+0.23), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
CytRx up on trial results
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:39AM CST
CYTR: 2.96 (+0.23)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:15AM CST
ARWR: 6.77 (+0.21), BBRY: 10.09 (+0.23), NADL: 2.10 (-0.02), FXCM: 2.21 (-0.01), CYN: 90.32 (+0.49), PBR: 6.98 (+0.44), XLNX: 41.51 (+0.51), NERV: 4.68 (+0.09), FWM: 5.55 (+0.08), CYTR: 2.96 (+0.23), FFIV: 116.64 (+1.37), LOGI: 14.86 (-0.02), LE: 35.84 (+0.19), SNDK: 82.81 (+0.51)
CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma
PR Newswire - Thu Jan 22, 8:00AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced encouraging overall survival (OS) results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS).
CYTR: 2.96 (+0.23)
CytRx Relieved as FDA Lifts Partial Hold on Oncology Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:15PM CST
CytRx Corporation (CYTR) received good news when the FDA removed the partial clinical hold on its oncology candidate aldoxorubicin.
SHPG: 239.82 (+6.11), CYTR: 2.96 (+0.23), LLY: 70.56 (+0.03), BIOD: 1.38 (-0.14)
Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jan 21, 10:02AM CST
The hepatitis C virus (HCV) pricing battle is heating up with Gilead (GILD) signing on with quite a few PBMs and health care benefit companies for Sovaldi and Harvoni.
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), CYTR: 2.96 (+0.23), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), CELG: 115.88 (+0.16)
Advaxis: Heavily Promoted And Misleading Investors
Richard Pearson - Seeking Alpha - Wed Jan 21, 8:30AM CST
We are just a few weeks into the year, and already shares of Advaxis (NASDAQ: ADXS ) are up by more than 60%. But that's nothing. The shares have fully quadrupled since their November lows. Advaxis stock has suddenly become extremely liquid, trading...
ADXS: 7.18 (+0.06), KITE: 62.59 (+0.82), CYTR: 2.96 (+0.23), JUNO: 40.52 (+0.18), GALE: 1.68 (+0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 8:16AM CST
BCS: 15.77 (+0.12), ANV: 0.97 (-0.03), FRO: 2.96 (+0.07), BAK: 9.02 (+0.03), UNIS: 4.32 (+0.06), EXPR: 14.61 (+0.33), ASPS: 22.32 (+0.09), ISR: 1.34 (-0.06), AU: 12.33 (+0.36), MHR: 2.62 (+0.11), SAP: 69.09 (unch), CPL: 13.01 (+0.33), CYTR: 2.96 (+0.23), ARNA: 4.55 (+0.02), SWHC: 12.63 (-0.20), EHTH: 10.91 (-0.04), OUTR: 68.39 (+2.22)
CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
PR Newswire - Tue Jan 20, 5:00AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's aldoxorubicin clinical trials. Enrollment and dosing of new patients is now permitted after study sites' Institutional Review Boards (IRBs) approve the revised trial protocols.
CYTR: 2.96 (+0.23)
What's To Like About CytRx's Brain Cancer Data?
Investing Healthcare - at Seeking Alpha - Tue Jan 20, 2:37AM CST
CYTR: 2.96 (+0.23), IMUC: 0.54 (-0.03)
CytRx up on interim trial results for KS in HIV patients
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:50AM CST
CYTR: 2.96 (+0.23)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma (KS)
PR Newswire - Thu Jan 08, 8:00AM CST
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients. The clinical results reported are from 9 patients, 6 of which carried the worst KS prognosis. Also, 4 of the 9 patients had received from 1 to 8 prior liposomal doxorubicin (Doxil®) cycles. Efficacy results revealed that all 9 patients (100%) exhibited a decrease in skin lesions and in the number of cancer cells expressing the KS virus DNA. Of the 6 patients with lung tumors, 4 patients (66%) demonstrated either a partial or complete response, with no patients (0%) demonstrating progression. Data thus far show that aldoxorubicin can be detected in all tumor biopsies 24 hours following drug administration. Preliminary safety results showed only 2 patients (22%) experienced a grade 4 adverse event (transient neutropenia and anemia). Other adverse events were mild and most were unrelated to aldoxorubicin.
CYTR: 2.96 (+0.23)
CytRx Jumps on Positive Results from Brain Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:16PM CST
CytRx Corporation (CYTR) jumped 15.8% after announcing encouraging interim results from a phase II study on aldoxorubicin.
MRK: 58.81 (-0.07), CYTR: 2.96 (+0.23), AMAG: 41.49 (+0.23)
Driving the Market: Special Research on Twitter, Frontline, CytRx, Tonix and American Electric
PR Newswire - Wed Jan 07, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Twitter (NYSE: TWTR), Frontline (NYSE: FRO), CytRx (NASDAQ: CYTR), Tonix (NASDAQ: TNXP), and American Electric (NYSE: AEP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AEP: 57.83 (-0.15), FRO: 2.96 (+0.07), TNXP: 5.78 (-0.02), CYTR: 2.96 (+0.23), TWTR: 48.50 (+0.55)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)
Stock to Watch: CytRx Up 21.1% (CYTR)
Comtex SmarTrend(R) - Tue Jan 06, 10:30AM CST
CytRx (NASDAQ:CYTR) is one of today's best performing low-priced stocks, up 21.1% to $3.45 on 14.5x average daily volume. CytRx has traded 10.1 million shares thus far today, vs. average volume of 701,000 shares per day. The stock has outperformed the Dow (21.1% to the Dow's -0.2%) and outperformed the S&P 500 (21.1% to the S&P's -0.2%) during today's trading.
CYTR: 2.96 (+0.23)
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics
PR Newswire - Wed Feb 04, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Celgene Corporation (NASDAQ: CELG), CytRx Corporation (NASDAQ: CYTR), Amicus Therapeutics Inc. (NASDAQ: FOLD), and United Therapeutics Corporation (NASDAQ: UTHR). Free research report on ARIAD Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=ARIAD%20P...amp;s=ARIA. On Tuesday, February 03, 2015, the NASDAQ Composite ended at 4,727.74, up 1.09%, the Dow Jones Industrial Average advanced 1.76%, to finish the day at 17,666.40, and the S&P 500 closed at 2,050.03, up 1.44%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 811.48, up 0.65%, with the index also advancing 4.16% in the previous three months. Register for your complimentary reports at the links given below.
UTHR: 151.11 (+3.59), CYTR: 2.96 (+0.23), ARIA: 7.35 (+0.45), FOLD: 8.36 (-0.11), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
CytRx to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015 in New York City
PR Newswire - Mon Feb 02, 8:00AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 5:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
CYTR: 2.96 (+0.23)
CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 3:45PM CST
CytRx Corporation (CYTR) announced encouraging data on its oncology candidate, aldoxorubicin.
JNJ: 99.62 (+1.18), CYTR: 2.96 (+0.23), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
CytRx up on trial results
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:39AM CST
CYTR: 2.96 (+0.23)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:15AM CST
ARWR: 6.77 (+0.21), BBRY: 10.09 (+0.23), NADL: 2.10 (-0.02), FXCM: 2.21 (-0.01), CYN: 90.32 (+0.49), PBR: 6.98 (+0.44), XLNX: 41.51 (+0.51), NERV: 4.68 (+0.09), FWM: 5.55 (+0.08), CYTR: 2.96 (+0.23), FFIV: 116.64 (+1.37), LOGI: 14.86 (-0.02), LE: 35.84 (+0.19), SNDK: 82.81 (+0.51)
CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma
PR Newswire - Thu Jan 22, 8:00AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced encouraging overall survival (OS) results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS).
CYTR: 2.96 (+0.23)
CytRx Relieved as FDA Lifts Partial Hold on Oncology Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:15PM CST
CytRx Corporation (CYTR) received good news when the FDA removed the partial clinical hold on its oncology candidate aldoxorubicin.
SHPG: 239.82 (+6.11), CYTR: 2.96 (+0.23), LLY: 70.56 (+0.03), BIOD: 1.38 (-0.14)
Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jan 21, 10:02AM CST
The hepatitis C virus (HCV) pricing battle is heating up with Gilead (GILD) signing on with quite a few PBMs and health care benefit companies for Sovaldi and Harvoni.
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), CYTR: 2.96 (+0.23), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), CELG: 115.88 (+0.16)
Advaxis: Heavily Promoted And Misleading Investors
Richard Pearson - Seeking Alpha - Wed Jan 21, 8:30AM CST
We are just a few weeks into the year, and already shares of Advaxis (NASDAQ: ADXS ) are up by more than 60%. But that's nothing. The shares have fully quadrupled since their November lows. Advaxis stock has suddenly become extremely liquid, trading...
ADXS: 7.18 (+0.06), KITE: 62.59 (+0.82), CYTR: 2.96 (+0.23), JUNO: 40.52 (+0.18), GALE: 1.68 (+0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 8:16AM CST
BCS: 15.77 (+0.12), ANV: 0.97 (-0.03), FRO: 2.96 (+0.07), BAK: 9.02 (+0.03), UNIS: 4.32 (+0.06), EXPR: 14.61 (+0.33), ASPS: 22.32 (+0.09), ISR: 1.34 (-0.06), AU: 12.33 (+0.36), MHR: 2.62 (+0.11), SAP: 69.09 (unch), CPL: 13.01 (+0.33), CYTR: 2.96 (+0.23), ARNA: 4.55 (+0.02), SWHC: 12.63 (-0.20), EHTH: 10.91 (-0.04), OUTR: 68.39 (+2.22)
CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
PR Newswire - Tue Jan 20, 5:00AM CST
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's aldoxorubicin clinical trials. Enrollment and dosing of new patients is now permitted after study sites' Institutional Review Boards (IRBs) approve the revised trial protocols.
CYTR: 2.96 (+0.23)
What's To Like About CytRx's Brain Cancer Data?
Investing Healthcare - at Seeking Alpha - Tue Jan 20, 2:37AM CST
CYTR: 2.96 (+0.23), IMUC: 0.54 (-0.03)
CytRx up on interim trial results for KS in HIV patients
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:50AM CST
CYTR: 2.96 (+0.23)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma (KS)
PR Newswire - Thu Jan 08, 8:00AM CST
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients. The clinical results reported are from 9 patients, 6 of which carried the worst KS prognosis. Also, 4 of the 9 patients had received from 1 to 8 prior liposomal doxorubicin (Doxil®) cycles. Efficacy results revealed that all 9 patients (100%) exhibited a decrease in skin lesions and in the number of cancer cells expressing the KS virus DNA. Of the 6 patients with lung tumors, 4 patients (66%) demonstrated either a partial or complete response, with no patients (0%) demonstrating progression. Data thus far show that aldoxorubicin can be detected in all tumor biopsies 24 hours following drug administration. Preliminary safety results showed only 2 patients (22%) experienced a grade 4 adverse event (transient neutropenia and anemia). Other adverse events were mild and most were unrelated to aldoxorubicin.
CYTR: 2.96 (+0.23)
CytRx Jumps on Positive Results from Brain Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:16PM CST
CytRx Corporation (CYTR) jumped 15.8% after announcing encouraging interim results from a phase II study on aldoxorubicin.
MRK: 58.81 (-0.07), CYTR: 2.96 (+0.23), AMAG: 41.49 (+0.23)
Driving the Market: Special Research on Twitter, Frontline, CytRx, Tonix and American Electric
PR Newswire - Wed Jan 07, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Twitter (NYSE: TWTR), Frontline (NYSE: FRO), CytRx (NASDAQ: CYTR), Tonix (NASDAQ: TNXP), and American Electric (NYSE: AEP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AEP: 57.83 (-0.15), FRO: 2.96 (+0.07), TNXP: 5.78 (-0.02), CYTR: 2.96 (+0.23), TWTR: 48.50 (+0.55)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)
Stock to Watch: CytRx Up 21.1% (CYTR)
Comtex SmarTrend(R) - Tue Jan 06, 10:30AM CST
CytRx (NASDAQ:CYTR) is one of today's best performing low-priced stocks, up 21.1% to $3.45 on 14.5x average daily volume. CytRx has traded 10.1 million shares thus far today, vs. average volume of 701,000 shares per day. The stock has outperformed the Dow (21.1% to the Dow's -0.2%) and outperformed the S&P 500 (21.1% to the S&P's -0.2%) during today's trading.
CYTR: 2.96 (+0.23)
